Compounds and methods for treatment of head and neck cancer
AssigneeInnate Pharma
InventorsOLIVIER BENAC, STÉPHANIE CHANTEUX, IVAN PERROT, BENJAMIN ROSSI, NICOLAS VIAUD
Life of this patent
Estimating the term…
Abstract
This invention relates to the use of ILT-2-targeting agents for the treatment of cancers head and neck cancers. This invention also provides advantageous combination regimens for use with ILT-2-targeting agents for the treatment of cancers.
Claims16
1-30. (canceled)
A method of treating an individual who has a head and neck squamous cell carcinoma (HNSCC), the method comprising administering to the individual an antibody that binds a human ILT-2 polypeptide and neutralizes the inhibitory activity of ILT-2 in combination with cetuximab.
A method of treating an individual who has an HNSCC, the method comprising administering to the individual an antibody that binds a human ILT-2 polypeptide and neutralizes the inhibitory activity of ILT-2 in combination with cetuximab, wherein the treatment is further in combination with an antibody that neutralizes the inhibitory activity of PD-1.
A pharmaceutical composition comprising an antibody that binds ILT-2 and an antibody that binds EGFR, wherein the antibody that binds ILT-2 has an Fc domain that is modified to reduce binding between the Fc domain and an Fcγ receptor.
A kit comprising a pharmaceutical composition containing an antibody that binds a human ILT-2 polypeptide and neutralizes the inhibitory activity of ILT-2, and a second pharmaceutical composition containing an anti-EGFR antibody, and instructions to administer said anti-EGFR antibody with an anti-ILT-2 antibody.
Dependencies are inferred from the claim text.